Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating two treatment approaches for patients with high anatomic stage breast cancer that has a low risk of returning. This phase III trial compares standard hormone therapy combined with ribociclib to chemotherapy followed by hormone therapy and ribociclib. Ribociclib works by blocking enzymes needed for tumor growth, and hormone therapy reduces estrogen levels to help stop the growth of cancer cells that depend on estrogen. Chemotherapy works differently by killing or stopping the division and spread of tumor cells. Participants are first screened using the Oncotype DX test to assess their recurrence risk. Those with scores between 0 and 25 are randomized into one of two groups. One group receives their physicians choice of chemotherapy followed by hormone therapy letrozole, anastrozole, or exemestane plus ribociclib. The other group receives hormone therapy plus ribociclib without chemotherapy. Hormone therapy is taken daily for at least 60 months, and ribociclib is taken daily for up to 3 years unless disease progression or unacceptable side effects occur. Throughout the study, participants may undergo imaging scans such as CT, bone scans, or FDG PET-CT scans, and may optionally provide blood samples. Participants are monitored with follow-up visits every 3 months for the first year, every 6 months during years 1 to 5, and annually from years 5 to 10 after randomization. Researchers will assess invasive breast cancer-free survival as the main outcome, along with disease-free survival, overall survival, recurrence measures, and both short- and long-term side effects. The study also plans to collect tumor tissue and blood samples to support future research. Total participation may last up to 10 years to evaluate long-term outcomes and safety.